193 related articles for article (PubMed ID: 35018250)
1. Alpha-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving immune checkpoint inhibitors with or without tyrosine kinase inhibitors or locoregional therapies.
Hsu WF; Wang HW; Chen CK; Lai HC; Chuang PH; Tsai MH; Su WP; Chen HY; Chu CS; Chou JW; Chen SH; Tsai TY; Hsiao WD; Lin CC; Huang GT; Lin JT; Peng CY
Am J Cancer Res; 2021; 11(12):6173-6187. PubMed ID: 35018250
[TBL] [Abstract][Full Text] [Related]
2. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
3. Combined CRAFITY score and α-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving anti-programmed death-1 blockade-based immunotherapy.
Hsu WF; Lai HC; Chen CK; Wang HW; Chuang PH; Tsai MH; Chen SH; Chu CS; Su WP; Chou JW; Kao JT; Chen HY; Chuang SC; Tsai TY; Hsiao WD; Huang GT; Peng CY
Am J Cancer Res; 2023; 13(2):654-668. PubMed ID: 36895987
[TBL] [Abstract][Full Text] [Related]
4. Predictors of response and survival in patients with unresectable hepatocellular carcinoma treated with nivolumab: real-world experience.
Hsu WF; Chuang PH; Chen CK; Wang HW; Tsai MH; Su WP; Chen HY; Yang CY; Lin CC; Huang GT; Lin JT; Lai HC; Peng CY
Am J Cancer Res; 2020; 10(12):4547-4560. PubMed ID: 33415018
[TBL] [Abstract][Full Text] [Related]
5. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma.
Shao YY; Liu TH; Hsu C; Lu LC; Shen YC; Lin ZZ; Cheng AL; Hsu CH
Liver Int; 2019 Nov; 39(11):2184-2189. PubMed ID: 31400295
[TBL] [Abstract][Full Text] [Related]
6. Development and Assessment of Nomogram Based on AFP Response for Patients with Unresectable Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors.
Zhang Y; Shen H; Zheng R; Sun Y; Xie X; Lu MD; Liu B; Huang G
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958306
[TBL] [Abstract][Full Text] [Related]
7. Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis.
Tian BW; Yan LJ; Ding ZN; Liu H; Meng GX; Xue JS; Han CL; Dong ZR; Hong JG; Chen ZQ; Wang DX; Li T
Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):73-83. PubMed ID: 36476076
[TBL] [Abstract][Full Text] [Related]
8. Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma.
Pinato DJ; Li X; Mishra-Kalyani P; D'Alessio A; Fulgenzi CAM; Scheiner B; Pinter M; Wei G; Schneider J; Rivera DR; Pazdur R; Theoret MR; Casak S; Lemery S; Fashoyin-Aje L; Cortellini A; Pelosof L
JHEP Rep; 2023 Jun; 5(6):100747. PubMed ID: 37197442
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma.
Lee PC; Chao Y; Chen MH; Lan KH; Lee CJ; Lee IC; Chen SC; Hou MC; Huang YH
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31940757
[TBL] [Abstract][Full Text] [Related]
10. Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Teng W; Lin CC; Su CW; Lin PT; Hsieh YC; Chen WT; Ho MM; Wang CT; Chai PM; Hsieh JC; Lin CY; Lin SM
Am J Cancer Res; 2022; 12(4):1899-1911. PubMed ID: 35530282
[TBL] [Abstract][Full Text] [Related]
11. Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy.
Luo MC; Wu JY; Wu JY; Lin ZT; Li YN; Zeng ZX; Wei SM; Yan ML
J Hepatocell Carcinoma; 2023; 10():1827-1837. PubMed ID: 37850079
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
Wang R; Lin N; Mao B; Wu Q
J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
[TBL] [Abstract][Full Text] [Related]
13. Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma.
Kim HI; Lim J; Shim JH
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2069-2077. PubMed ID: 34459972
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients.
Han CL; Tian BW; Yan LJ; Ding ZN; Liu H; Mao XC; Tian JC; Xue JS; Tan SY; Dong ZR; Yan YC; Hong JG; Chen ZQ; Wang DX; Li T
Cancer Immunol Immunother; 2023 Jul; 72(7):1957-1969. PubMed ID: 36811662
[TBL] [Abstract][Full Text] [Related]
15. Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitor.
Lin PT; Hsu YC; Kao YT; Teng W; Hsieh YC; Chen WT; Su CW; Wang CT; Chai PM; Lin CC; Lin CY; Lin SM
Am J Cancer Res; 2024; 14(3):1306-1315. PubMed ID: 38590407
[TBL] [Abstract][Full Text] [Related]
16. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies.
Zhang L; Feng J; Kuang T; Chai D; Qiu Z; Deng W; Dong K; Zhao K; Wang W
Int Immunopharmacol; 2023 May; 118():110019. PubMed ID: 36933492
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
[TBL] [Abstract][Full Text] [Related]
18. Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients.
Zhang J; Wang L; Zhang S; Cao R; Zhao Y; Zhao Y; Song Y; Guo Z
BMC Cancer; 2024 Feb; 24(1):266. PubMed ID: 38408930
[TBL] [Abstract][Full Text] [Related]
19. Hepatic arterial infusion chemotherapy and immune checkpoint inhibitors, alone or in combination, in advanced hepatocellular carcinoma with macrovascular invasion: a single-centre experience in Taiwan.
Wu JS; Hong TC; Wu HT; Lin YJ; Chang TT; Wang CT; Liu WC; Hsieh MT; Wu IC; Chen PJ; Chen CY; Lin SH; Chuang CH; Han MZ; Chen HP; Tsai HM; Kuo HY
J Gastrointest Oncol; 2023 Apr; 14(2):849-862. PubMed ID: 37201085
[TBL] [Abstract][Full Text] [Related]
20. A Real-World Experience on a Chinese Population of Patients With Unresectable Hepatocellular Carcinoma Treated With Nivolumab.
Lee SW; Yang SS; Lee TY
Gastroenterology Res; 2024 Feb; 17(1):15-22. PubMed ID: 38463150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
